|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Warburg Pincus, a leading private equity firm. |
|---|---|
| Transferring Party | Lifecore Biomedical, Inc. (Nasdaq (LCBM), a maker of dental implant systems, tissue regeneration products and other biomaterials. |
| Sector | Dental |
| Date | January 15, 2008 |
| Analysis Continues Warburg's torrid acquistion program in the medical device area, investing more $1b since 1989 in some 20 deals. Lifecore’s oral restorative products are surgically placed into the jawbone, which maintains underlying bone structure and provides fixation of restorations. As a private company, Lifecore will have greater flexibility to meet long-term strategic goals. Deal value -- $239m, on sales of $71.0m (3.4x) and EBITDA of $13.1m (18.2x). | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |